Skip to main content

Prohance Side Effects

Generic name: gadoteridol

Medically reviewed by Last updated on Dec 10, 2023.

Note: This document contains side effect information about gadoteridol. Some dosage forms listed on this page may not apply to the brand name Prohance.

Applies to gadoteridol: intravenous solution.


Intravenous route (Solution)

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the drugs.. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe renal insufficiency (GFR less than 30 mL/min/1.73 m(2)), or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, age greater than 60 years, hypertension, or diabetes), estimate the GFR through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended gadoteridol dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration.

Serious side effects of Prohance

Along with its needed effects, gadoteridol (the active ingredient contained in Prohance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking gadoteridol:


Incidence not known

Other side effects of Prohance

Some side effects of gadoteridol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


For Healthcare Professionals

Applies to gadoteridol: intravenous solution.


Cardiovascular side effects have included prolonged P-R Interval, hypotension, elevated heart rate, A-V nodal rhythm, cardiac arrest, bradycardia, hypertension, and death in association with pre-existing cardiovascular disorders.[Ref]


Respiratory side effects have included dyspnea, rhinitis, cough, apnea, and wheezing.[Ref]


Other side effects have included voice alteration; transitory deafness and tinnitus.[Ref]

Nervous system

Nervous system side effects have included headache, anxiety, dizziness, paresthesia, mental status decline, loss of coordination in arm, staring episodes, seizure, syncope, stupor, tremor, tingling sensation in extremities and digits, and loss of consciousness.[Ref]


Hypersensitivity side effects have included anaphylactoid reactions rarely resulting in death.[Ref]


Dermatologic side effects have included pruritus, rash, macular papular rash, urticaria, hives, itching, sweating, and cyanosis.[Ref]


Gastrointestinal side effects have included edematous and/or itching tongue, gingivitis dry mouth, loose bowel, vomiting, abdominal cramps, increased salivation, and dysphagia.[Ref]


General side effects have included facial edema, neck rigidity, pain, chest pain, fever, tingling sensation in throat, laryngismus, flushed feeling, vasovagal reaction, and generalized edema.[Ref]


Genitourinary side effects have included urinary incontinence.[Ref]


Local side effects have included pain at injection site and injection site reaction.[Ref]


Ocular side effects have included watery eyes.


1. Product Information. ProHance (gadoteridol). Bracco Diagnostics Inc. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.